Fluidigm Announces First Quarter 2019 Financial Results
02 mai 2019 16h05 HE
|
Fluidigm Corporation
First quarter revenue increased 19 percent to $30.1 million Mass cytometry revenue growth of 110 percent in first quarter Strong mass cytometry and Imaging Mass Cytometry instrument adoption First...
Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting
28 mars 2019 08h45 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Participate in Upcoming Investor Conferences
22 févr. 2019 17h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results
07 févr. 2019 16h05 HE
|
Fluidigm Corporation
Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to $113.0 millionIncluding...
Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1
31 janv. 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, today announced the introduction of a...
Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results
14 janv. 2019 16h05 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report...
Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares
14 déc. 2018 16h05 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its...
Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference
12 nov. 2018 16h05 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s...
Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018
08 nov. 2018 08h30 HE
|
Fluidigm Corporation
A comprehensive suite of innovative immuno-oncology applications to improve the future of cancer care SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation...
Fluidigm Recognized as a Company to Watch in 2019
07 nov. 2018 16h11 HE
|
Fluidigm Corporation
Immuno-oncology innovator receives life science people’s choice award SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- BioInformatics Inc., the leading research and advisory firm...